Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Blood Purif ; 52(11-12): 898-904, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37879297

RESUMEN

INTRODUCTION: During the height of the coronavirus disease-19 (COVID-19) pandemic, some renal replacement therapy (RRT) modalities were insufficient, forcing medical centers to diversify the RRT modalities offered. In this study, we reported the outcomes of chronic peritoneal dialysis (PD) patients and acute PD in critically ill patients during COVID-19 pandemic in a tertiary care medical center in Mexico. METHODS: This descriptive, longitudinal, observational, retrospective study included 47 adult patients with atypical pneumonia in a tertiary care medical center in Mexico during the first and second waves of the COVID-19 pandemic. Chronic PD patients and PD incident patients due to acute kidney injury (AKI) were included. RESULTS: Forty-seven patients were studied (29 chronic PD patients and 18 incident PD patients due to AKI); median age was 59 (48-68) years; 63.8% were men. The ultrafiltrate volume per day was 815 (596.1-1,193.2) mL. Overall mortality was 61.7%, 55.2% in chronic PD patients, and 72.2% in PD incident patients due to AKI. A higher Sequential Organ Failure Assessment (SOFA) score, the need for mechanical ventilation at admission, and the requirement for vasopressors were predictors for mortality (p < 0.01). CONCLUSION: In low- and lower-middle-income countries, PD was a valid alternative for RRT during the COVID-19 pandemic. In AKI patients, PD can correct hyperkalemia, acidosis, uremia, and volume overload; however, there was higher mortality in PD incident patients due to AKI. The main risk factors for mortality were a high SOFA score at admission, the need for invasive mechanical ventilation, and the requirement for vasopressors.


Asunto(s)
Lesión Renal Aguda , COVID-19 , Diálisis Peritoneal , Masculino , Adulto , Humanos , Persona de Mediana Edad , Femenino , COVID-19/terapia , COVID-19/complicaciones , Pandemias , Estudios Retrospectivos , México/epidemiología , Países en Desarrollo , Unidades de Cuidados Intensivos , Diálisis Peritoneal/efectos adversos , Terapia de Reemplazo Renal/efectos adversos , Lesión Renal Aguda/etiología , Lesión Renal Aguda/terapia , Lesión Renal Aguda/epidemiología
2.
Blood Purif ; 50(3): 283-289, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33017826

RESUMEN

In December 2019, cases of acute respiratory illness of unknown origin were reported in Wuhan, China. The disease is caused by "severe acute respiratory syndrome coronavirus 2". After identifying severe lung damage, injury to other organs, such as the kidney, has been identified. Peritoneal dialysis is a renal replacement therapy (RRT) and is at least as effective as other extracorporeal therapy options, with significant cost-effective advantages. However, this strategy is rarely used for the management of acute kidney injury in severe lung disease. In this review, we explore PD as an RRT strategy that may be a key instrument in countries and hospitals with limited access to all RRTs.


Asunto(s)
Lesión Renal Aguda/terapia , COVID-19/complicaciones , Pandemias , Diálisis Peritoneal , SARS-CoV-2 , Lesión Renal Aguda/etiología , Lesión Pulmonar Aguda/etiología , Líquido Ascítico/virología , COVID-19/prevención & control , Cateterismo/métodos , Contención de Riesgos Biológicos , Citocinas/metabolismo , Países en Desarrollo , Manejo de la Enfermedad , Humanos , Control de Infecciones , Inflamación , Eliminación de Residuos Sanitarios , Posición Prona , SARS-CoV-2/patogenicidad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA